Research Article

Proinflammatory Factors Mediate Paclitaxel-Induced Impairment of Learning and Memory

Zhao Li,1 Shuang Zhao,1 Hai-Lin Zhang,2 Peng Liu,1 Fei-Fei Liu,1 Yue-Xian Guo,3 and Xiu-Li Wang 1

1Department of Anesthesiology, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, China
2Department of Pharmacology, Hebei Medical University, Shijiazhuang 050017, China
3Department of Urology, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, China

Correspondence should be addressed to Xiu-Li Wang; wangxl311@126.com

Received 29 September 2017; Revised 17 December 2017; Accepted 8 January 2018; Published 22 February 2018

Academic Editor: Luis I. Terrazas

Copyright © 2018 Zhao Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The chemotherapeutic agent paclitaxel is widely used for cancer treatment. Paclitaxel treatment impairs learning and memory function, a side effect that reduces the quality of life of cancer survivors. However, the neural mechanisms underlying paclitaxel-induced impairment of learning and memory remain unclear. Paclitaxel treatment leads to proinflammatory factor release and neuronal apoptosis. Thus, we hypothesized that paclitaxel impairs learning and memory function through proinflammatory factor-induced neuronal apoptosis. Neuronal apoptosis was assessed by TUNEL assay in the hippocampus. Protein expression levels of tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) in the hippocampus tissue were analyzed by Western blot assay. Spatial learning and memory function were determined by using the Morris water maze (MWM) test. Paclitaxel treatment significantly increased the escape latencies and decreased the number of crossing in the MWM test. Furthermore, paclitaxel treatment increased the number of TUNEL-positive neurons in the hippocampus. Also, paclitaxel treatment increased the expression levels of TNF-α and IL-1β in the hippocampus tissue. In addition, the TNF-α synthesis inhibitor thalidomide significantly attenuated the number of paclitaxel-induced TUNEL-positive neurons in the hippocampus and restored the impaired spatial learning and memory function in paclitaxel-treated rats. These data suggest that TNF-α is critically involved in the paclitaxel-induced impairment of learning and memory function.

1. Introduction

The chemotherapeutic agent paclitaxel is widely used to treat patients with breast, ovarian, and lung cancers [1–5]. By binding to β-tubulin within the microtubules, paclitaxel stabilizes the microtubule lattice to suppress depolymerization and dynamic instability [6]. Paclitaxel treatment induces mild to moderate cognitive impairment known as “chemo-brain” in some cancer survivors [7–12]. Compared with the 8% incidence rate of cognitive concerns in participants without a prior cancer diagnosis, an approximately 14% incidence rate of cancer survivors with memory problems represents a 40% increase in cancer survivors who have cognitive concerns [13]. However, the mechanisms underlying paclitaxel-induced neurological dysfunction remain unclear.

Previous studies have shown that the neuropathy of paclitaxel is limited to peripheral sensory nerves through affecting axonal degeneration in sensory nerves [14–16] because paclitaxel does not cross the blood-brain barrier (BBB) [17]. However, by using positron emission tomography (PET), radiolabeled paclitaxel was detectable in the brain tissues after intravenous administration [18], suggesting that a small amount of paclitaxel may cross the BBB to act on brain tissue. Furthermore, paclitaxel induces apoptosis in neurons through a mechanism distinct from that of nonneuronal cells [19]. In this regard, paclitaxel induces apoptosis through endoplasmic reticulum stress [20]. The hippocampus, cortex, and striatum are the core regions in the limbic system [21] and play critical roles in spatial learning and memory as well as cognitive processes [22, 23].
However, the mechanisms underlying the neurotoxicity of paclitaxel on hippocampus neurons are not clear.

Paclitaxel increases the production of TNF-α in macrophages and endothelial cells [24–26] by promoting TNF-α gene expression [27]. TNF-α is a membrane-integrated proinflammatory cytokine which is produced by activated macrophages and monocytes [28]. TNF-α can induce cell death or a cell-protective effect depending on the receptor it binds to TNF-α receptor 1 (TNFR1) or 2 (TNFR2) [29, 30]. TNF-α preferentially binds to TNFR1 which contains a death-effector domain to induce caspase-8 cleavage and apoptosis [31, 32]. It has been shown that TNF-α can initiate apoptosis of neurons [33–35] and oligodendrocytes [36, 37]. Therefore, we hypothesized that neuronal apoptosis caused by proinflammatory factors contributes to paclitaxel-induced impairment of neurological function.

2. Materials and Methods

Male Sprague-Dawley (SD) rats (6–8 weeks old, 200–300 g) were used in this study. The experimental protocol was approved by the Use Committee of the Hebei Medical University according to the guidelines of using animals (K2016-020-3). All efforts were made to minimize both the suffering and the number of rats used. The rats were numbered during the study. The number identity of the rats was revealed during data analysis. Quantitative data were analyzed by staff blinded to group-identifying information.

2.1. Learning and Memory Tests Using Morris Water Maze.

Male SD rats were randomly assigned into experimental groups for MWM test following randomized numbers generated by the GraphPad software. The sample size and power were determined by using according to the data obtained from our pilot studies by using the SPSS Statistics analysis software. The rats were closely observed by staff from the lab and animal facility for fatal signals and any abnormal behaviors such as pain, distress, and infection, as described in the animal protocol. The MWM testing experiments were performed by staff blinded to treatment conditions. The water maze container filled with opaque water was 150 cm in diameter and 50 cm in height of the wall. The water level was 32 cm in height. The escape platform was 30 cm in height and 15 cm in diameter. The MWM tests were performed before and every 4 days after paclitaxel and vehicle treatment (an average of values of 4 tests during the testing day). The escape latency and the number of crossings over the platform location were analyzed and plotted.

2.2. Paclitaxel Treatment.

Paclitaxel was dissolved in a vehicle solution containing a mixture of saline and 10% Cremophor EL, a derivative of castor oil and ethylene oxide, which is clinically used for paclitaxel injection. Vehicle or paclitaxel solution was administered intraperitoneally (i.p.) in a dosage of 2 ml/kg/day. After habituation to the test environment and baseline measurement of behavioral tests, paclitaxel or vehicle was injected administered to these 2 groups of rats on 4 consequent days (days 1, 3, 5, and 7) with paclitaxel dose of 8 mg/kg [38]. TNF-α inhibitor thalidomide was administered orally (100 mg/kg/day) for 4 days during paclitaxel treatment [39]. The treatment schedule is illustrated in Figure 1.

2.3. Western Blot Assay.

The Western blot analysis was performed by staff blinded to treatment conditions. Under deep anesthesia by intraperitoneal injection of pentobarbital (60 mg/kg), the rat was decapitated and the hippocampus tissue was removed and homogenized in RIPA lysis buffer containing proteinase F. An equal amount of protein (60 μg) was loaded into each lane, separated electrophoretically by SDS-PAGE and electroblotted onto PVDF membranes. After blocking for 1 h in 5% nonfat dry milk, the membrane was incubated with anti-TNF-α and anti-IL-1β and anti-GAPDH (Santa Cruz) at 4°C overnight. The membrane was rinsed and incubated with horseradish peroxidase-conjugated goat anti-rabbit secondary antibody at 1 : 4000 dilutions for 3 h at 37°C. The membrane was developed by using an enhanced chemiluminescence kit according to the manufacturer’s instruction. The blotting was captured digitally, and the intensity of the band was quantified by the Kodak EDAS 120 system and Quantity One 4.6 software. The density of each band was normalized to GAPDH expression.

2.4. TUNEL Assay.

For visualization of neuronal apoptosis in the hippocampus, we performed terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay to assess apoptotic cell death in rats treated by vehicle, paclitaxel, thalidomide, and paclitaxel and thalidomide. In brief, the rats were anesthetized and perfused with 200 ml of 0.9% normal saline with 0.1% of heparin, followed by 200 ml PBS containing 4% paraformaldehyde. Brains were removed and placed in 4% paraformaldehyde to postfix for 24 h at room temperature. Then, the brains were dehydrated and sectioned into brain slices at a thickness of 16 μm. An In Situ Cell Death Detection Kit (TMR Green; Roche Applied Sciences, Indianapolis, IN) was used to determine the number of apoptotic cells. Ten sections randomly selected from each group were fixed in ethanol-acetic acid at −20°C. The sections were incubated with proteinase K, rinsed, and incubated with 3% H2O2 at room temperature. Then, 0.5% Triton X-100 was used to permeabilize the cell membrane followed by incubation with the TUNEL reaction mixture (6 μl per section) at 37°C. The sections were then visualized using Converter-POD with 0.02% 3,3′-diaminobenzidine (DAB; 100 μl/section) at room temperature. Then, the sections were counterstained with hematoxylin for 30 seconds and washed again with running water for 10 minutes. Cell counting was performed in the CA1 subfield of the dorsal hippocampus. Cells with brown nuclei were considered apoptotic and were analyzed by using the Image-Pro 6.0 software (Media Cybernetics Inc., Rockville, MD, USA). The number of TUNEL-positive cells was quantified under ×400 magnification, and the density of stained cells was presented as cells per square millimeter.

2.5. Statistical Analysis.

All data were expressed as mean ± SEM, and the data were analyzed by the SPSS 13.0 software
3. Results

3.1. Paclitaxel Impairs Spatial Memory in the MWM Test. It has been shown that acute application of paclitaxel impairs cognitive function in mice [40]. Thus, we first determined the cognitive function in rats subjected to chronic paclitaxel treatment by performing the MWM test. The escape latencies and the number of crossings over the hidden escape platform beneath the water were significantly decreased in the later trails following the initial trial and reached a stable level at trial numbers 5 to 9 in vehicle-treated rats (n = 15). Another group of rats (n = 15) was treated with paclitaxel (2.0 mg/kg/day for 4 days, i.p.). Paclitaxel treatment significantly increased the duration of escape latencies and the number of crossings over the platform compared with vehicle-treated rats (Figures 2(a) and 2(b)). These data suggest that chronic paclitaxel impairs spatial learning and memory.

3.2. Paclitaxel-Induced Hippocampal Neuronal Apoptosis. We performed TUNEL staining to evaluate cell apoptosis in the hippocampus. Paclitaxel treatment significantly increased the number of TUNEL-positive cells in the hippocampus compared with vehicle-treated rats (P < 0.05, Figure 3). Treatment with thalidomide, a TNF-α synthesis inhibitor, did not change the number of TUNEL-positive cells in vehicle-treated rats. However, thalidomide treatment significantly reduced the number of TUNEL-positive cells in paclitaxel-treated rats in the hippocampal CA1 region (Figure 3).

3.3. Paclitaxel Increases Expression Levels of Proinflammatory Cytokines. Then, the expression levels of proinflammatory cytokines TNF-α and IL-1β in the hippocampus were determined in the vehicle- and paclitaxel-treated rats. We performed Western immunoblotting analysis by using antibodies against TNF-α and IL-1β in hippocampal tissues obtained from rats treated with vehicle, paclitaxel, and paclitaxel with thalidomide (TNF-α inhibitor, 100 mg/kg/day). Western immunoblotting showed a single band for TNF-α or IL-1β. Paclitaxel treatment significantly increased the band density for both TNF-α and IL-1β (Figure 4). However, thalidomide application reduced the TNF-α and IL-1β expression levels in paclitaxel-treated rats. Thalidomide treatment had no effect on the expression levels in vehicle-treated rats.

3.4. Inhibition of TNF-α Rescued the Impairment of Spatial Learning and Memory Induced by Paclitaxel. Next, we determined the effect of the TNF-α inhibitor on spatial learning and memory in rats subjected to chronic paclitaxel treatment. The rats in each group received the injection of vehicle, paclitaxel (2 mg/kg/day, i.p.) for 4 days, and paclitaxel plus oral administration of thalidomide (100 mg/kg/day) for 4 days. During the MWM test, the rats in each group showed a daily improvement in their ability to locate the hidden platform. Paclitaxel treatment significantly increased the escape latencies and the number of crossings compared with vehicle-treated rats (Figure 5). Thalidomide treatment restored the increased escape latencies and the number of crossings in paclitaxel-treated rats, while it had no effect on escape latencies and the number of crossings in vehicle-

(SPS Inc., Chicago, IL, USA). For comparisons of more than 2 groups, the repeated measures ANOVA with Dunnett’s post hoc test or one-way ANOVA with Bonferroni’s post hoc test was performed to compare responses within or between experimental groups (GraphPad Prism 6). P < 0.05 was considered statistically significant.
treated rats. These data suggest that inhibition of TNF-α restores paclitaxel-induced impairment of spatial learning and memory.

4. Discussion

For the first time, this study demonstrated that chronic systemic administration of paclitaxel impaired spatial learning and memory function through TNF-α. Hippocampal cell apoptosis caused by paclitaxel may contribute to the impairment of this neurological function. We found that inhibition of TNF-α synthesis restored the impaired learning and memory function in paclitaxel-treated rats. Furthermore, TNF-α synthesis inhibition eliminated paclitaxel-induced cell apoptosis in the hippocampus. These findings provide new information about the neurotoxicity of paclitaxel and for developing new therapeutics to treat the side effects of paclitaxel through targeting TNF-α.

Paclitaxel is one of the most effective chemotherapeutic agents for the treatment of various types of cancer. By stabilizing microtubules, paclitaxel treatment causes mitochondrial damage and p53-independent cell apoptosis through blocking of the G2/M cell cycle [41–44]. The limitation for the usage of paclitaxel in cancer treatment includes neurotoxicity during paclitaxel therapy [45]. For example, systemic administration of paclitaxel produces painful peripheral neuropathies [46, 47]. We found in this study that paclitaxel significantly increased the escape latency and decreased the number of crossings over the hidden platform. These findings suggest that paclitaxel impairs spatial learning and memory function. Our findings are consistent with commonly reported cognition defects associated with chemotherapy treatment in cancer patients [48, 49]. It has been shown that paclitaxel impairs learning and memory function in rodents [50–52]. However, paclitaxel does not affect all forms of cognition. For example, systemic administration of paclitaxel does not impair spatial and episodic memory in a radial arm maze procedure that requires the animal to remember the source of information [38]. However, early studies have shown that paclitaxel does not cross the blood-brain barrier (BBB) to affect neurons in the central nervous system [17]. However, later studies using positron emission tomography (PET) found that radio-labeled paclitaxel was detectable in the brain after intravenous administration [18]. Systemic administration of paclitaxel may penetrate at a low rate into the central nervous system to affect cognitive function. Thus, it is possible that paclitaxel may directly cause hippocampal neuronal apoptosis. However, the concentration of paclitaxel in the hippocampus may not be high enough to cause neuronal apoptosis during paclitaxel treatment.

Consistent with previous studies showing that paclitaxel can induce apoptosis of neurons [19, 20], we found that paclitaxel treatment increased the number of TUNEL-positive neurons in the hippocampus. Paclitaxel induces neuronal apoptosis through a mechanism distinct from that in nonneuronal cells. In this regard, by stabilizing microtubules, paclitaxel induces apoptosis in cancer and nonneuronal cells.

**Figure 2:** Paclitaxel impairs spatial learning and memory in the Morris water maze test. Summary data showing the escape latency (a) and the number of crossings (b) over the platform during a series of testing before and after paclitaxel or vehicle treatment. Representative swimming paths on the 12th day after paclitaxel or vehicle treatment (c). Data are expressed as mean ± SEM. *P < 0.05 compared with the vehicle-treated group.
Paclitaxel induces apoptosis in cortical neurons by a mechanism independent of Bcl-2 phosphorylation [19]. Paclitaxel also induces endoplasmic reticulum stress to cause neuronal apoptosis [20]. We found that paclitaxel induces hippocampal neuronal apoptosis associated with an increase in expression levels of TNF-α and IL-1β in the hippocampus tissue. One possible mechanism is that paclitaxel activates the p38 MAPK/NF-κB pathway in peripheral macrophages and monocytes. The activation of NF-κB promotes the expression of various proinflammatory genes including TNF-α, IL-1β, and interleukin-6 (IL-6) [55]. The circulating TNF-α released from peripheral macrophages and monocytes increases the permeability of the BBB [56, 57]. Thus, both TNF-α and paclitaxel possibly penetrate the BBB to access the central nervous system. Consequently, TNF-α activates the NF-κB signaling pathway and inflammatory responses in neural tissues such as microglia, astrocytes, and neurons. It has been shown that sustained activation of the NF-κB-TNF-α pathway triggers neuroinflammatory response to promote local neuronal apoptosis [33, 58].

Previous studies have shown that paclitaxel is capable of increasing the expression of IL-1β in primary human monocytes, T lymphocytes, human breast cancer cell lines [59], and macrophages [60]. Because paclitaxel led to IL-1β synthesis in macrophages at early time points but secreted it at following time points [60], it is likely that TNF-α triggers the release of IL-1β from macrophages. It should be noted that TNF-α is a cytokine produced predominantly by macrophages and it stimulates macrophages to release inflammatory cytokines [61]. This notion is supported by the finding that the TNF-α inhibitor also decreased IL-1β protein expression levels. This is not a nonspecific effect because the TNF-α inhibitor alone did not change the expression level in control rats. It has been shown that a high plasma level of proinflammatory cytokine IL-6 is associated with the occurrence of cognitive impairment.
**Figure 4:** Paclitaxel increased the expression levels of TNF-α and IL-1β. Representative gel images (a and b) and summary data (c and d) show the TNF-α (a) and IL-1β (b) protein expression levels in the hippocampus tissue from rats treated with vehicle, paclitaxel, thalidomide, and paclitaxel plus thalidomide (n = 6 rats in each group). Data in (c) and (d) are expressed as mean ± SEM. *P < 0.05 compared with the vehicle group. #P < 0.05 compared with the PTX group. PTX: paclitaxel; THD: thalidomide.

**Figure 5:** The TNF-α synthesis inhibitor thalidomide restored paclitaxel-induced impairment of spatial learning and memory. Representative swimming paths (a) on the 12th day after vehicle, paclitaxel, thalidomide, and paclitaxel plus thalidomide treatment. Summary data showing the escape latency for finding the platform (b) and the number of crossings over the platform (c) during a series of testing in the group of rats receiving vehicle, paclitaxel, and paclitaxel plus thalidomide. Data are expressed as mean ± SEM. *P < 0.05 compared with the vehicle group. PTX: paclitaxel; THD: thalidomide.
in postchemotherapy breast cancer patients [62]. This high level of IL-6 may result from paclitaxel-induced TNF-α. However, in this study, we did not determine the role of IL-6 in paclitaxel-induced impairment of learning and memory as well as neuronal apoptosis in the hippocampus. Thus, the role of IL-6 in mediating paclitaxel-induced responses warrants further studies.

In summary, our findings indicate that paclitaxel treatment induces neuronal apoptosis through the upregulation of TNF-α. Inhibition of TNF-α synthesis with thalidomide rescued paclitaxel-induced impairment of spatial learning and memory function. Our findings identified a novel mechanism underlying paclitaxel-induced impairment of cognitive function. Findings from this study provide new insight into the mechanisms underlying paclitaxel-induced impairment of spatial learning and memory and new targets for the development of novel therapy of neurological dysfunctions during chemotherapy by targeting TNF-α.

Abbreviations

TNF-α: Tumor necrosis factor-α
IL-1β: Interleukin-1β
IL-6: Interleukin-6
MWM: Morris water maze.

Additional Points

Highlights. (i) Paclitaxel induces impairment of learning and memory function. (ii) The behavior impairment induced by paclitaxel is associated with an increase in TNF-α expression level and apoptotic cells in the hippocampus. (iii) Inhibition of TNF-α synthesis recovered the impaired learning and memory function in paclitaxel-treated rats.

Conflicts of Interest

The authors declare no conflict of interest.

Authors’ Contributions

Xiu-Li Wang, Zhao Li, Yue-Xian Guo, and Hai-Lin Zhang participated in the research design. Zhao Li, Shuang Zhao, Peng Liu, and Fei-Fei Liu conducted the experiments. Zhao Li, Shuang Zhao, Peng Liu, and Xiu-Li Wang performed the data analysis. Zhao Li, Shuang Zhao, Peng Liu, Xiu-Li Wang, Yue-Xian Guo, and Hai-Lin Zhang wrote or contributed to the writing of the manuscript.

Acknowledgments

This study was supported by grants from the National Natural Science Foundation of China (81372131) and the Natural Science Foundation of Hebei Province (H2013206087) to Dr. Xiu-Li Wang.

References

[1] T. S. Collins, L. F. Lee, and J. P. Ting, "Paclitaxel up-regulates interleukin-8 synthesis in human lung carcinoma through an NF-κB- and AP-1-dependent mechanism," Cancer Immunology, Immunotherapy, vol. 49, no. 2, pp. 78–84, 2000.
[2] S. Honore, K. Kamath, D. Braguer et al., "Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells," Cancer Research, vol. 64, no. 14, pp. 4957–4964, 2004.
[3] J. R. Hsiao, S. F. Leu, and B. M. Huang, "Apoptotic mechanism of paclitaxel-induced cell death in human head and neck tumor cell lines," Journal of Oral Pathology & Medicine, vol. 38, no. 2, pp. 188–197, 2009.
[4] G. Li, J. Zhao, X. Peng, J. Liang, X. Deng, and Y. Chen, "Radiation/paclitaxel treatment of p53-abnormal non-small cell lung cancer xenograft tumor and associated mechanism," Cancer Biotherapy & Radiopharmaceuticals, vol. 27, no. 4, pp. 227–233, 2012.
[5] H. Wang, B. Liu, C. Zhang et al., "Parker regulates paclitaxel sensitivity in breast cancer via a microtubule-dependent mechanism," The Journal of Pathology, vol. 218, no. 1, pp. 76–85, 2009.
[6] E. Nogales, S. G. Wolf, I. A. Khan, R. F. Luduena, and K. H. Downing, "Structure of tubulin at 6.5 Å and location of the taxol-binding site," Nature, vol. 375, no. 6530, pp. 424–427, 1995.
[7] T. A. Ahles, A. J. Saykin, C. T. Furstenberg et al., "Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma," Journal of Clinical Oncology, vol. 20, no. 2, pp. 485–493, 2002.
[8] C. B. Brezden, K. A. Phillips, M. Abdoell, T. Bunston, and I. F. Tannock, "Cognitive function in breast cancer patients receiving adjuvant chemotherapy," Journal of Clinical Oncology, vol. 18, no. 14, pp. 2695–2701, 2000.
[9] D. Panoz-Brown, L. M. Carey, A. E. Smith et al., "The chemotherapeutic agent paclitaxel selectively impairs reversal learning while sparing prior learning, new learning and episodic memory," Neurobiology of Learning and Memory, vol. 144, pp. 259–270, 2017.
[10] S. B. Schagen, F. S. van Dam, M. J. Muller, W. Boogerd, J. Lindeboom, and P. F. Bruning, "Structure of tubulin at 6.5 Å and location of the taxol-binding site," Nature, vol. 375, no. 6530, pp. 424–427, 1995.
[11] I. F. Tannock, T. A. Ahles, P. A. Ganz, and F. S. Van Dam, "Cognitive impairment associated with chemotherapy for cancer: report of a workshop," Journal of Clinical Oncology, vol. 22, no. 11, pp. 2233–2239, 2004.
[12] N. Tchen, H. G. Juffis, F. P. Downie et al., "Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer," Cancer, vol. 85, no. 3, pp. 640–650, 1999.
[13] P. Jean-Pierre, P. C. Winters, T. A. Ahles et al., "Prevalence of self-reported memory problems in adult cancer survivors: a national cross-sectional study," Journal of Oncology Practice, vol. 8, no. 1, pp. 30–34, 2012.
[14] E. Gornstein and T. L. Schwarz, "The paradox of paclitaxel neurotoxicity: mechanisms and unanswered questions," Neuropharmacology, vol. 76, Part A, pp. 175–183, 2014.
[15] S. Quasthoff and H. P. Hartung, "Chemotherapy-induced peripheral neuropathy," Journal of Neurology, vol. 249, no. 1, pp. 9–17, 2002.
epidermal innervation and activation of Langerhans cells,” Experimental Neurology, vol. 201, no. 2, pp. 507–514, 2006.

[17] S. B. Park, C. S. Lin, A. V. Krishnan, M. L. Friedlander, C. R. Lewis, and M. C. Kiernan, “Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy,” Muscle & Nerve, vol. 43, no. 3, pp. 367–374, 2011.

[18] A. Gangloff, W. A. Hsueh, A. L. Kesner et al., “Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with 31P-fluoroplatinaxil,” Journal of Nuclear Medicine, vol. 46, no. 11, pp. 1866–1871, 2005.

[19] X. A. Figueroa-Masot, M. Hetman, M. J. Higgins, N. Kokot, and Z. Xia, “Taxol induces apoptosis in cortical neurons by a mechanism independent of Bcl-2 phosphorylation,” The Journal of Neuroscience, vol. 21, pp. 4657–4667, 2001.

[20] H. Tanimukai, D. Kanayama, T. Omi, M. Takeda, and M. Grell, G. Zimmermann, D. Hulser, K. Pfizzenmaier, and P. Scheurich, “TNF receptors TR60 and TR80 can mediate apoptosis via induction of distinct signal pathways,” Journal of Immunology, vol. 153, pp. 1963–1972, 1994.

[21] E. T. Rolls, “Memory, learning while sparing source memory and spatial memory, but no single limbic system,” Cortex, vol. 62, pp. 119–157, 2015.

[22] J. Czerniawski, T. Miyashita, G. Lewandowski, and J. F. Guzowski, “Systemic lipopolysaccharide administration impairs retrieval of context–object discrimination, but not spatial, memory: evidence for selective disruption of specific hippocampus-dependent memory functions during acute neuroinflammation,” Brain Behavior & Immunity, vol. 44, pp. 159–166, 2014.

[23] S. E. Kanoski and H. J. Grill, “Hippocampus contributions to food intake control: mnemonic, neuroanatomical, and endocrine mechanisms,” Biological Psychiatry, vol. 81, no. 9, pp. 748–756, 2017.

[24] C. Bogdan and A. Ding, “Taxol, a microtubule-stabilizing anti-neoplastic agent, induces expression of tumor necrosis factor alpha and interleukin-1 in macrophages,” Journal of Leukocyte Biology, vol. 52, no. 1, pp. 119–121, 1992.

[25] C. S. Wood, X. Tang, and B. Tesfamariam, “Paclitaxel potentiates inflammatory cytokine-induced prothrombotic molecules in endothelial cells,” Journal of Cardiovascular Pharmacology, vol. 55, no. 3, pp. 276–285, 2010.

[26] Z. Wu, S. Wang, I. Wu, M. Mata, and D. J. Fink, “Activation of TLR-4 to produce tumour necrosis factor alpha in neuropathic pain caused by paclitaxel,” European Journal of Pain, vol. 19, no. 7, pp. 889–898, 2015.

[27] Y. Zhu, Z. Yao, Z. Wu, Y. Mei, and M. Wu, “Role of tumor necrosis factor alpha-induced protein 1 in paclitaxel resistance,” Oncogene, vol. 33, no. 25, pp. 3246–3255, 2014.

[28] F. Meloni, “Tumor necrosis factor alpha. Biological aspects,” Giornale Italiano di Chemo terapia, vol. 36, no. 1-3, pp. 29–37, 1989.

[29] D. J. MacEwan, “TNF ligands and receptors – a matter of life and death,” British Journal of Pharmacology, vol. 135, no. 4, pp. 855–875, 2002.

[30] D. J. MacEwan, “TNF receptor subtype signalling: differences and cellular consequences,” Cellular Signalling, vol. 14, no. 6, pp. 477–492, 2002.

[31] M. Grell, G. Zimmermann, D. Hulser, K. Pfizzenmaier, and P. Scheurich, “TNF receptors TR60 and TR80 can mediate apoptosis via induction of distinct signal pathways,” Journal of Immunology, vol. 153, pp. 1963–1972, 1994.

[32] H. Hsu, J. Xiong, and D. V. Goeddel, “The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation,” Cell, vol. 81, no. 4, pp. 495–504, 1995.

[33] S. D’Souza, K. Alinauskas, E. Micreva, C. Goodyer, and J. P. Antel, “Differential susceptibility of human CNS-derived cell populations to TNF-dependent and independent immune-mediated injury,” The Journal of Neuroscience, vol. 15, no. 11, pp. 7293–7300, 1995.

[34] G. U. Enzmann, R. L. Benton, J. F. Talbott, Q. Cao, and S. R. Whittemore, “Functional considerations of stem cell transplantation therapy for spinal cord repair,” Journal of Neurotrauma, vol. 23, no. 3-4, pp. 479–495, 2006.

[35] L. Wang, F. X. Wei, J. S. Cen et al., “Early administration of tumor necrosis factor-alpha antagonist promotes survival of transplanted neural stem cells and axon myelination after spinal cord injury in rats,” Brain Research, vol. 1575, pp. 87–100, 2014.

[36] K. Akassoglou, J. Bauer, G. Kassiotis et al., “Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy,” The American Journal of Pathology, vol. 153, no. 3, pp. 801–813, 1998.

[37] T. Inukai, K. Uchida, H. Nakajima et al., “Tumor necrosis factor-alpha and its receptors contribute to apoptosis of oligodendrocytes in the spinal cord of spinal hyperostotic mouse (tww/twx) sustaining chronic mechanical compression,” Spine, vol. 34, no. 26, pp. 2848–2857, 2009.

[38] A. E. Smith, R. A. Slivicki, A. G. Hohmann, and J. D. Crystal, “The chemotherapeutic agent paclitaxel selectively impairs learning while sparing source memory and spatial memory,” Behavioural Brain Research, vol. 320, pp. 48–57, 2017.

[39] K. Amirshahrkhoji and A. R. Khalili, “Thalidomide ameliorates cisplatin-induced nephotoxicity by inhibiting renal inflammation in an experimental model,” Inflammation, vol. 38, no. 2, pp. 476–484, 2015.

[40] D. Astarod, G. Eskandari-Sedighi, F. Pazhoohi, S. M. Karimian, M. Khajeloo, and G. H. Riazi, “Microtubule dynamicity is more important than stability in memory formation: an in vivo study,” Journal of Molecular Neuroscience, vol. 56, no. 2, pp. 313–319, 2015.

[41] A. M. Barbuti and Z. S. Chen, “Paclitaxel through the ages of anticancer therapy; exploring its role in chemoresistance and radiation therapy,” Cancers, vol. 7, no. 4, pp. 2360–2371, 2015.

[42] S. B. Horwitz, L. Tholstein, J. J. Manfredi et al., “Taxol: mechanisms of action and resistance,” Annals of the New York Academy of Sciences, vol. 466, no. 1 Dynamic Aspec, pp. 733–744, 1986.

[43] P. B. Schiff, J. Fant, and S. B. Horwitz, “Promotion of microtubule assembly in vitro by taxol,” Nature, vol. 277, no. 5698, pp. 665–667, 1979.

[44] B. A. Weaver, “How taxol/paclitaxel kills cancer cells,” Molecular Biology of the Cell, vol. 25, no. 18, pp. 2677–2681, 2014.

[45] C. N. Frederiks, S. W. Lam, H. J. Guchelaar, and E. Boven, “Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: a systematic review,” Cancer Treatment Reviews, vol. 41, no. 10, pp. 935–950, 2015.

[46] S. Mielke, A. Sparreboom, and K. Mross, “Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes,” European Journal of Cancer, vol. 42, no. 1, pp. 24–30, 2006.
[47] C. D. Scripture, W. D. Figg, and A. Sparreboom, “Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives,” Current Neuropharmacology, vol. 4, no. 2, pp. 165–172, 2006.

[48] T. A. Ahles and A. J. Saykin, “Candidate mechanisms for chemotherapy-induced cognitive changes,” Nature Reviews Cancer, vol. 7, no. 3, pp. 192–201, 2007.

[49] J. S. Wefel and S. B. Schagen, “Chemotherapy-related cognitive dysfunction,” Current Neurology and Neuroscience Reports, vol. 12, no. 3, pp. 267–275, 2012.

[50] C. K. Callaghan and S. M. O’ Mara, “Long-term cognitive dysfunction in the rat following docetaxel treatment is ameliorated by the phosphodiesterase-4 inhibitor, rolipram,” Behavioural Brain Research, vol. 290, pp. 84–89, 2015.

[51] J. E. Fardell, J. Vardy, and I. N. Johnston, “The short and long term effects of docetaxel chemotherapy on rodent object recognition and spatial reference memory,” Life Sciences, vol. 93, pp. 596–604, 2013.

[52] J. E. Fardell, J. Zhang, R. De Souza et al., “The impact of sustained and intermittent docetaxel chemotherapy regimens on cognition and neural morphology in healthy mice,” Psychiatry, vol. 231, pp. 841–852, 2014.

[53] M. A. Jordan, K. Wendell, S. Gardiner, W. B. Derry, H. Copp, and L. Wilson, “Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death,” Cancer Research, vol. 56, no. 4, pp. 816–825, 1996.

[54] A. L. Kung, A. Zetterberg, S. W. Sherwood, and R. T. Schimke, “Cytotoxic effects of cell cycle phase specific agents: result of cell cycle perturbation,” Cancer Research, vol. 50, pp. 7307–7317, 1990.

[55] T. Liu, L. Zhang, D. Joo, and S. C. Sun, "NF-κB signaling in inflammation," Signal Transduction and Targeted Therapy, vol. 2, article 17023, 2017.

[56] W. Wang, S. Lv, Y. Zhou, J. Fu, C. Li, and P. Liu, “Tumor necrosis factor-α affects blood–brain barrier permeability in acetaminophen-induced acute liver failure,” European Journal of Gastroenterology & Hepatology, vol. 23, no. 7, pp. 552–558, 2011.

[57] G. Y. Yang, C. Gong, Z. Qin, X. H. Liu, and A. Lorris Betz, “Tumor necrosis factor alpha expression produces increased blood–brain barrier permeability following temporary focal cerebral ischemia in mice,” Molecular Brain Research, vol. 69, no. 1, pp. 135–143, 1999.

[58] A. Maqbool, M. Lattke, T. Wirth, and B. Baumann, “Sustained, neuron-specific IKK/NF-κB activation generates a selective neuroinflammatory response promoting local neurodegeneration with aging,” Molecular Neurodegeneration, vol. 8, no. 1, p. 40, 2013.

[59] C. M. White, B. K. Martin, L. F. Lee, J. S. Haskill, and J. P. Ting, “Effects of paclitaxel on cytokine synthesis by unprimed human monocytes, T lymphocytes, and breast cancer cells,” Cancer Immunology, Immunotherapy, vol. 46, no. 2, pp. 104–112, 1998.

[60] T. Voloshin, D. Alishkevitz, L. Kaneti et al., “Blocking IL1β pathway following paclitaxel chemotherapy slightly inhibits primary tumor growth but promotes spontaneous metastasis,” Molecular Cancer Therapeutics, vol. 14, no. 6, pp. 1385–1394, 2015.

[61] D. W. Riches, E. D. Chan, and B. W. Winston, “TNF-α-induced regulation and signalling in macrophages,” Immunobiology, vol. 195, no. 4-5, pp. 477–490, 1996.

[62] J. W. Chae, T. Ng, H. L. Yeo et al., “Impact of TNF-α (rs1800629) and IL-6 (rs1800795) polymorphisms on cognitive impairment in Asian breast cancer patients,” PLoS One, vol. 11, no. 10, article e0164204, 2016.